Randomized controlled trials (RTCs) remain the unique cornerstones to serve as the best possible level of evidence and best possible sources for meta-analyses and systematic reviews 3 and ultimately the best possible drivers to assign appropriate grades of recommendation 4 as indicators and arbiters of therapeutic efficiency of clinical management options. Naturally, conception, design, planning, cost implications, sustained efforts, time, and execution for potentially successful completion and publication of RCTs as the pinnacle of evidence constitute a formidable undertaking from the beginning to the end. Therefore, RCTs are in a class of their own and demand due diligence at each step from inception to minimize questionable aspects pertaining to comprehensive design, data analysis, bias, and conclusions.
Journal made a commendable combined editorial stand to require registration in a publicly searchable clinical trials registry prior to review for publication of RCTs and the registry number would be published in electronic and print versions. Until the end of 2017 during a transition, this registration could be prospective or retrospective, but as of January 1, 2018, authors of all RCTs that began after publication of the editorial must demonstrate proof of prospective registration. 3 It is clear that top scientific journals, as publication mediums and leaders of scientific publication, have a crucial role as guardians to defend the bastions of evidence at the frontiers and cutting edge of scientific evidence and practice. We believe that it is time that Foot & Ankle International, as the leading international foot and ankle publication, also undertakes this policy to ensure mandatory prospective registration of RCTs in a publicly searchable clinical trials registry before considering review for publication from January 1, 2020. RCTs, which started after the date of electronic publication of this editorial policy for Foot & Ankle International (FAI) in the transition period in 2019, as well as RCTs with satisfactory evidence of starting before electronic publication of the editorial policy for FAI, shall be allowed retrospective registration in a publicly searchable clinical trials registry prior to review and potential publication. The Editorial Board, however, will reserve the right to make rare exceptions in the event of unusual studies in extenuating circumstances following guidance from the editor in chief with an explanatory note from the authors regarding the reasons and an editorial note for the exception, published as a footnote in the article.
Facilitating collective altruism, trust, and transparency as hallmarks of ethical research practice ultimately inspires professional and public confidence in research. 1 Mandatory registration of RCTs in an accessible and searchable registry may be construed as an optimal starting point of transparency and a source of demonstrable means to an end to facilitate a robust basis of the level of evidence and grade of recommendation for excellence in contemporary clinical practice.
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